Nadia Harbeck1. 1. Breast Center, Department of OB&GYN, University of Munich (LMU) Munich, Germany.
Abstract
PURPOSE OF REVIEW: Breast cancer is the most common malignancy in women and HER2-positive disease comprises about 15% of all breast cancer cases. Over the last few years, substantial advances have been made in treatment of early breast cancer (EBC) and advanced (ABC) HER2-positive (HER2+) breast cancer. The present review summarizes the major publications on HER2+ breast cancer in the year 2017 and discusses their clinical relevance. RECENT FINDINGS: The clinically most relevant data in 2017 relates to the EBC setting. The St. Gallen Consensus 2017 for the first time recommended neoadjuvant treatment as standard of care in HER2+ EBC. Moreover, the APHINITY trial demonstrated efficacy of adjuvant dual antibody-based HER2 blockade. Data in MBC mostly confirmed established treatment strategies. SUMMARY: Clinical data presented in 2017 for HER2+ breast cancer confirmed current guidelines and extended treatment options for patients. First intriguing steps were made towards de-escalation in the EBC setting.
PURPOSE OF REVIEW: Breast cancer is the most common malignancy in women and HER2-positive disease comprises about 15% of all breast cancer cases. Over the last few years, substantial advances have been made in treatment of early breast cancer (EBC) and advanced (ABC) HER2-positive (HER2+) breast cancer. The present review summarizes the major publications on HER2+ breast cancer in the year 2017 and discusses their clinical relevance. RECENT FINDINGS: The clinically most relevant data in 2017 relates to the EBC setting. The St. Gallen Consensus 2017 for the first time recommended neoadjuvant treatment as standard of care in HER2+ EBC. Moreover, the APHINITY trial demonstrated efficacy of adjuvant dual antibody-based HER2 blockade. Data in MBC mostly confirmed established treatment strategies. SUMMARY: Clinical data presented in 2017 for HER2+ breast cancer confirmed current guidelines and extended treatment options for patients. First intriguing steps were made towards de-escalation in the EBC setting.
Authors: Evangelos Prokakis; Anna Dyas; Regina Grün; Sonja Fritzsche; Upasana Bedi; Zahra B Kazerouni; Robyn L Kosinsky; Steven A Johnsen; Florian Wegwitz Journal: Oncogene Date: 2021-05-18 Impact factor: 9.867
Authors: Catarina Almeida-Ferreira; Rafael Silva-Teixeira; Ana Cristina Gonçalves; Carlos Miguel Marto; Ana Bela Sarmento-Ribeiro; Francisco Caramelo; Maria Filomena Botelho; Mafalda Laranjo Journal: Int J Mol Sci Date: 2022-02-01 Impact factor: 5.923
Authors: Christine Brezden-Masley; Kelly E Fathers; Megan E Coombes; Behin Pourmirza; Cloris Xue; Katarzyna J Jerzak Journal: Breast Cancer Res Treat Date: 2020-10-22 Impact factor: 4.872